M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 5.99 PLN -0.66% Market Closed
Market Cap: 123.4m PLN

Operating Margin
Molecure SA

-496.2%
Current
-2 328%
Average
6.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-496.2%
=
Operating Profit
-25.4m
/
Revenue
5.1m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
PL
Molecure SA
WSE:MOC
123.4m PLN
-496%
US
Eli Lilly and Co
NYSE:LLY
971B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
479.2B USD
27%
CH
Roche Holding AG
SIX:ROG
245.2B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.1B GBP
24%
CH
Novartis AG
SIX:NOVN
195.9B CHF
33%
US
Merck & Co Inc
NYSE:MRK
240.1B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
202B USD
11%
US
Pfizer Inc
NYSE:PFE
142.9B USD
29%
No Stocks Found

Molecure SA
Glance View

Market Cap
123.4m PLN
Industry
Pharmaceuticals

Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.

MOC Intrinsic Value
4.47 PLN
Overvaluation 25%
Intrinsic Value
Price
M
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-496.2%
=
Operating Profit
-25.4m
/
Revenue
5.1m
What is the Operating Margin of Molecure SA?

Based on Molecure SA's most recent financial statements, the company has Operating Margin of -496.2%.

Back to Top